Good morning! As we wrap up the week, let’s dive right into the latest news in the biotech industry.
Biopharma leaders are celebrating the Supreme Court’s ruling on the regulation of the abortion pill mifepristone. The industry had warned that a decision in favor of the plaintiffs could have disrupted the drug approval process. This ruling is seen as a win for the FDA, science, and women’s rights.
In other FDA news, there have been discussions on how to improve advisory committees to ensure patient voices are better heard and conflicts of interest are minimized. FDA Commissioner Robert Califf has been leading these conversations to make these expert meetings more effective.
On the podcast “The Readout LOUD,” Pfizer’s Duchenne gene therapy setback, Lilly’s Alzheimer’s drug endorsement, and Bob Langer’s latest startup are discussed. Additionally, STAT’s commercial determinants of health reporter shares insights on his unique approach to journalism, which includes buying items like weed and raw milk for stories.
A significant development in the biotech investment landscape is J.P. Morgan’s entry into early stage biotech investing. The J.P. Morgan Life Sciences Private Capital team has raised over $500 million to invest in startups focusing on obesity therapies, cardiometabolic disease treatments, and immune-driven conditions. This move marks a shift in traditional VC funding models, as J.P. Morgan plans to incubate and build new biotech companies.
As the biotech industry continues to evolve, it’s crucial to stay informed about the latest developments and investments shaping the future of healthcare. Stay tuned for more updates on the exciting advancements in biotech.
